{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:50:58Z","timestamp":1788565858330,"version":"build-2803163510"},"reference-count":106,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Transcatheter ablation was increasingly and successfully used to treat symptomatic drug refractory patients affected by supraventricular arrhythmias. Antiarrhythmic drug treatment still plays a major role in patient management, alone or combined with non-pharmacological therapies. Flecainide is an IC antiarrhythmic drug approved in 1984 from the Food and Drug Administration for the suppression of sustained ventricular tachycardia and later for acute cardioversion of atrial fibrillation and for sinus rhythm maintenance. Currently, flecainide is mostly used for sinus rhythm maintenance in atrial fibrillation (AF) patients without structural cardiomyopathy although recent studies enrolling different patient populations have demonstrated a good effectiveness and safety profile. How should we interpret the results of the CAST after the latest evidence? Is it possible to expand the indications of flecainide, and therefore, its use? This review aims to highlight the main characteristics of flecainide, as well as its optimal clinical use, delineating drug indications and contraindications and appropriate monitoring, based on the most recent evidence.<\/jats:p>","DOI":"10.3390\/jcm10071456","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T23:05:11Z","timestamp":1617318311000},"page":"1456","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Flecainide How and When: A Practical Guide in Supraventricular Arrhythmias"],"prefix":"10.3390","volume":"10","author":[{"given":"Carlo","family":"Lavalle","sequence":"first","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, \u201cSapienza\u201d University of Rome, Policlinico Umberto I, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9883-0114","authenticated-orcid":false,"given":"Michele","family":"Magnocavallo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, \u201cSapienza\u201d University of Rome, Policlinico Umberto I, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Straito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, \u201cSapienza\u201d University of Rome, Policlinico Umberto I, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Santini","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ospedale GB Grassi, 00121 Ostia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8895-8915","authenticated-orcid":false,"given":"Giovanni Battista","family":"Forleo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Azienda Ospedaliera-Universitaria \u201cLuigi Sacco\u201d, 20057 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ospedale Generale Regionale F. Miulli, Acquaviva delle Fonti, 70021 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Badagliacca","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, \u201cSapienza\u201d University of Rome, Policlinico Umberto I, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Lanata","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Domp\u00e9 Farmaceutici SpA, 20057 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato Pietro","family":"Ricci","sequence":"additional","affiliation":[{"name":"CardioArrhythmology Center, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"key":"ref_1","unstructured":"Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J.J., Blomstr\u00f6m-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., and Dilaveris, P.E. (2020). 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.15420\/aer.2018.56.2","article-title":"Percutaneous Treatment of Non-Paroxysmal Atrial Fibrillation: A Paradigm Shift from Pulmonary Vein to Non-Pulmonary Vein Trigger Ablation?","volume":"7","author":"Mohanty","year":"2018","journal-title":"Arrhythm. Electrophysiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial Fibrillation Management: A Prospective Survey in ESC Member Countries","volume":"26","author":"Nieuwlaat","year":"2005","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.jacc.2011.07.036","article-title":"Cardiovascular Outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management)","volume":"58","author":"Saksena","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1161\/CIRCOUTCOMES.114.001499","article-title":"Comparisons of Hospitalization Rates Among Younger Atrial Fibrillation Patients Receiving Different Antiarrhythmic Drugs","volume":"8","author":"Dai","year":"2015","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"B41","DOI":"10.1016\/0002-9149(84)90501-0","article-title":"Metabolism of Flecainide","volume":"53","author":"Conard","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1056\/NEJM198108273050901","article-title":"Oral Flecainide Acetate for the Treatment of Ventricular Arrhythmias","volume":"305","author":"Anderson","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2125.1986.tb02892.x","article-title":"Flecainide: Single and Multiple Oral Dose Kinetics, Absolute Bioavailability and Effect of Food and Antacid in Man","volume":"22","author":"Verbesselt","year":"1986","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198529010-00001","article-title":"Flecainide A Preliminary Review of Its Pharmacodynamic Properties and Therapeutic Efficacy","volume":"29","author":"Holmes","year":"1985","journal-title":"Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"B95","DOI":"10.1016\/0002-9149(84)90510-1","article-title":"Effects of Flecainide on Ventricular Function: Clinical and Experimental Correlations","volume":"53","author":"Josephson","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/cvr\/17.5.251","article-title":"Voltage- and Time-Dependent Depression of Maximum Rate of Depolarisation of Guinea-Pig Ventricular Action Potentials by Two New Antiarrhythmic Drugs, Flecainide and Lorcainide","volume":"17","author":"Campbell","year":"1983","journal-title":"Cardiovasc. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/01.RES.66.3.789","article-title":"Interactions of Flecainide with Guinea Pig Cardiac Sodium Channels. Importance of Activation Unblocking to the Voltage Dependence of Recovery","volume":"66","author":"Anno","year":"1990","journal-title":"Circ. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/01.CIR.82.1.289","article-title":"Block of Delayed Rectifier Potassium Current, IK, by Flecainide and E-4031 in Cat Ventricular Myocytes","volume":"82","author":"Follmer","year":"1990","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cardiores.2003.12.026","article-title":"Pharmacology of Cardiac Potassium Channels","volume":"62","author":"Tamargo","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1749-6632.1984.tb14522.x","article-title":"The Electrophysiology and Pharmacology of Verapamil, Flecainide, and Amiodarone: Correlations with Clinical Effects and Antiarrhythmic Actions","volume":"432","author":"Singh","year":"1984","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1124\/mol.114.094623","article-title":"Multiple Modes of Ryanodine Receptor 2 Inhibition by Flecainide","volume":"86","author":"Mehra","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_18","first-page":"260","article-title":"Effect of Flecainide on Cardiac Output","volume":"37","author":"Muhiddin","year":"1985","journal-title":"Clin. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0002-9149(83)80073-3","article-title":"Hemodynamic Effects of a New Antiarrhythmic Agent, Flecainide (R-818), in Coronary Heart Disease","volume":"51","author":"Legrand","year":"1983","journal-title":"Am. J. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0002-9149(81)90331-3","article-title":"Suppression of Resistant Ventricular Arrhythmias by Twice Daily Dosing with Flecainide","volume":"48","author":"Duff","year":"1981","journal-title":"Am. J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.CIR.65.5.879","article-title":"Suppression of Ventricular Ectopic Depolarizations by Flecainide Acetate, a New Antiarrhythmic Agent","volume":"65","author":"Hodges","year":"1982","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-8703(85)90413-2","article-title":"Hemodynamic Effects of Intravenous Flecainide Relative to the Level of Ventricular Function in Patients with Coronary Artery Disease","volume":"109","author":"Josephson","year":"1985","journal-title":"Am. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0735-1097(87)80096-7","article-title":"Influence of Left Ventricular Dysfunction on Flecainide Therapy","volume":"9","author":"Horowitz","year":"1987","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00005344-200305000-00015","article-title":"Pharmacodynamic Equivalence of Two Flecainide Acetate Formulations in Patients with Paroxysmal Atrial Fibrillation by QRS Analysis of Ambulatory Electrocardiogram","volume":"41","author":"Coumel","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_25","first-page":"112","article-title":"Pharmacokinetics and Electrocardiographic Effects of a New Controlled-Release Form of Flecainide Acetate: Comparison with the Standard Form and Influence of the CYP2D6 Polymorphism","volume":"72","author":"Tarral","year":"2002","journal-title":"Clin. Pharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1161\/01.CIR.90.6.2843","article-title":"Interaction of Baseline Characteristics with the Hazard of Encainide, Flecainide, and Moricizine Therapy in Patients with Myocardial Infarction. A Possible Explanation for Increased Mortality in the Cardiac Arrhythmia Suppression Trial (CAST)","volume":"90","author":"Anderson","year":"1994","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1161\/01.CIR.99.11.1499","article-title":"Cellular and Ionic Basis for T-Wave Alternans under Long-QT Conditions","volume":"99","author":"Shimizu","year":"1999","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)","volume":"36","author":"Priori","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Tarantino, N., Della Rocca, D.G., De Leon De La Cruz, N.S., Manheimer, E.D., Magnocavallo, M., Lavalle, C., Gianni, C., Mohanty, S., Trivedi, C., and Al-Ahmad, A. (2021). Catheter Ablation of Life-Threatening Ventricular Arrhythmias in Athletes. Medicina, 57.","DOI":"10.3390\/medicina57030205"},{"key":"ref_30","first-page":"370","article-title":"Long-Term Flecainide Therapy in Type 3 Long QT Syndrome","volume":"20","author":"Chorin","year":"2018","journal-title":"EP Eur."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.hrthm.2017.12.018","article-title":"Class IC Antiarrhythmic Drugs for Suspected Premature Ventricular Contraction\u2013Induced Cardiomyopathy","volume":"15","author":"Hyman","year":"2018","journal-title":"Heart Rhythm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/CRD.0000000000000040","article-title":"Novel Perspectives on Arrhythmia-Induced Cardiomyopathy: Pathophysiology, Clinical Manifestations and an Update on Invasive Management Strategies","volume":"23","author":"Santini","year":"2015","journal-title":"Cardiol. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.hrthm.2016.12.010","article-title":"Use of Flecainide in Combination Antiarrhythmic Therapy in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy","volume":"14","author":"Ermakov","year":"2017","journal-title":"Heart Rhythm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/pace.12426","article-title":"Left Ventricular Hypertrophy and Antiarrhythmic Drugs in Atrial Fibrillation: Impact on Mortality: Lvh, Antiarrhythmic Drugs, and Mortality","volume":"37","author":"Chung","year":"2014","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJM198607033150106","article-title":"Flecainide","volume":"315","author":"Roden","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0002-9149(85)90726-X","article-title":"Flecainide: Electrophysiologic and Antiarrhythmic Properties in Refractory Ventricular Tachycardia","volume":"55","author":"Platia","year":"1985","journal-title":"Am. J. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0002-9149(88)90282-2","article-title":"Supraventricular Tachycardia Mimicking Ventricular Tachycardia during Flecainide Treatment","volume":"62","author":"Crijns","year":"1988","journal-title":"Am. J. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.2165\/00003495-200464240-00003","article-title":"Pharmacological Cardioversion of Atrial Fibrillation: Current Management and Treatment Options","volume":"64","author":"Boriani","year":"2004","journal-title":"Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1055\/s-0031-1299923","article-title":"Meta-Analysis of Flecainide Safety in Patients with Supraventricular Arrhythmias","volume":"52","author":"Wehling","year":"2011","journal-title":"Arzneimittelforschung"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"B101","DOI":"10.1016\/0002-9149(84)90511-3","article-title":"Extracardiac Adverse Effects of Flecainide","volume":"53","author":"Gentzkow","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1161\/CIRCULATIONAHA.106.618421","article-title":"Effect of Amiodarone and Sotalol on Ventricular Defibrillation Threshold: The Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Trial","volume":"114","author":"Hohnloser","year":"2006","journal-title":"Circulation"},{"key":"ref_42","first-page":"419","article-title":"Electrophysiologic, Inotropic and Antiarrhythmic Effects of Propafenone, 5-Hydroxypropafenone and N-Depropylpropafenone","volume":"246","author":"Malfatto","year":"1988","journal-title":"J. Pharm. Exp."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"373.e1","DOI":"10.1016\/j.ahj.2008.01.032","article-title":"The Drug and Pace Health CliNical Evaluation (DAPHNE) Study: A Randomized Trial Comparing Sotalol versus \u03b2-Blockers to Treat Symptomatic Atrial Fibrillation in Patients with Brady-Tachycardia Syndrome Implanted with an Antitachycardia Pacemaker","volume":"156","author":"Capucci","year":"2008","journal-title":"Am. Heart J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ahj.2008.05.004","article-title":"The MINERVA Study Design and Rationale: A Controlled Randomized Trial to Assess the Clinical Benefit of Minimizing Ventricular Pacing in Pacemaker Patients with Atrial Tachyarrhythmias","volume":"156","author":"Funck","year":"2008","journal-title":"Am. Heart J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/hrt.2009.184523","article-title":"Atrial Tachyarrhythmias and Cardiac Resynchronisation Therapy: Clinical and Therapeutic Implications","volume":"96","author":"Lavalle","year":"2010","journal-title":"Heart"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1111\/j.1540-8159.1988.tb05992.x","article-title":"Implanted Automatic Defibrillators: Effects of Drugs and Pacemakers","volume":"11","author":"Singer","year":"1988","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0002-9149(88)91062-4","article-title":"Direct and Autonomically Mediated Effects of Oral Flecainide","volume":"61","author":"Alboni","year":"1988","journal-title":"Am. J. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"B30","DOI":"10.1016\/0002-9149(84)90499-5","article-title":"Electrophysiologic Effects of Flecainide Acetate on Sinus Node Function, Anomalous Atrioventricular Connections, and Pacemaker Thresholds","volume":"53","author":"Hellestrand","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0735-1097(83)80382-9","article-title":"Electrophysiologic and Antiarrhythmic Effects of Oral Flecainide in Patients with Inducible Ventricular Tachycardia","volume":"2","author":"Anderson","year":"1983","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/hrt.42.5.573","article-title":"Effects of Amiodarone on Sinus Node in Man","volume":"42","author":"Touboul","year":"1979","journal-title":"Br. Heart J."},{"key":"ref_51","first-page":"37","article-title":"Long Term Evaluation of Flecainide Acetate in Supraventricular Tachyarrhythmias","volume":"43","author":"Telerman","year":"1988","journal-title":"Acta Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0735-1097(86)80234-0","article-title":"Flecainide and Amiodarone Interaction","volume":"7","author":"Shea","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2165\/00003495-198500294-00014","article-title":"Logic and Empiricism in the Selection of Antiarrhythmic Agents: The Role of Drug Combinations","volume":"29","author":"Coumel","year":"1985","journal-title":"Drugs"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/europace\/euv462","article-title":"Flecainide\u2013Metoprolol Combination Reduces Atrial Fibrillation Clinical Recurrences and Improves Tolerability at 1-Year Follow-up in Persistent Symptomatic Atrial Fibrillation","volume":"18","author":"Capucci","year":"2016","journal-title":"Europace"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"B52","DOI":"10.1016\/0002-9149(84)90502-2","article-title":"Interaction of Flecainide with Digoxin and Propranolol","volume":"53","author":"Lewis","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00002018-200023060-00003","article-title":"Antiarrhythmic Agents: Drug Interactions of Clinical Significance","volume":"23","author":"Trujillo","year":"2000","journal-title":"Drug Saf."},{"key":"ref_57","first-page":"26","article-title":"The Pharmacodynamic and Pharmacokinetic Interaction between Single Doses of Flecainide Acetate and Verapamil: Effects on Cardiac Function and Drug Clearance","volume":"46","author":"Holtzman","year":"1989","journal-title":"Clin. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","article-title":"2019 ESC Guidelines for the Management of Patients with Supraventricular TachycardiaThe Task Force for the Management of Patients with Supraventricular Tachycardia of the European Society of Cardiology (ESC)","volume":"41","author":"Brugada","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_59","first-page":"1337","article-title":"Pharmacological and Non-Pharmacological Therapy for Arrhythmias in the Pediatric Population: EHRA and AEPC-Arrhythmia Working Group Joint Consensus Statement","volume":"15","author":"Brugada","year":"2013","journal-title":"EP Eur."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0735-1097(90)90555-4","article-title":"Supraventricular Tachycardia Due to Wolff-Parkinson-White Syndrome in Children: Early Disappearance and Late Recurrence","volume":"16","author":"Perry","year":"1990","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40272-017-0254-0","article-title":"Management of Supraventricular Tachycardia in Infants","volume":"19","author":"Richardson","year":"2017","journal-title":"Pediatr. Drugs"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"572","DOI":"10.7326\/0003-4819-144-8-200604180-00007","article-title":"Brief Communication: Atrial\u2013Esophageal Fistulas after Radiofrequency Ablation","volume":"144","author":"Cummings","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jpeds.2016.10.051","article-title":"Acute Management of Refractory and Unstable Pediatric Supraventricular Tachycardia","volume":"181","author":"Lewis","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00228-015-1832-0","article-title":"Narrow Therapeutic Index Drugs: A Clinical Pharmacological Consideration to Flecainide","volume":"71","author":"Tamargo","year":"2015","journal-title":"Eur. J. Clin. Pharm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0002-9149(00)01128-0","article-title":"Comparison of Intravenous Flecainide, Propafenone, and Amiodarone for Conversion of Acute Atrial Fibrillation to Sinus Rhythm","volume":"86","author":"Santos","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-126-8-199704150-00006","article-title":"Oral Propafenone To Convert Recent-Onset Atrial Fibrillation in Patients with and without Underlying Heart Disease: A Randomized, Controlled Trial","volume":"126","author":"Boriani","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0002-9149(94)90915-6","article-title":"Conversion of Recent-Onset Atrial Fibrillation by a Single Oral Loading Dose of Propafenone or Flecainide","volume":"74","author":"Capucci","year":"1994","journal-title":"Am. J. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/oxfordjournals.eurheartj.a062553","article-title":"Acute Conversion of Atrial Fibrillation to Sinus Rhythm: Clinical Efficacy of Flecainide Acetate. Comparison of Two Regimens","volume":"9","author":"Crijns","year":"1988","journal-title":"Eur. Heart J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1111\/j.1540-8159.1998.tb01203.x","article-title":"Conversion of Recent-Onset Atrial Fibrillation to Sinus Rhythm: Effects of Different Drug Protocols","volume":"21","author":"Boriani","year":"1998","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9149(92)91392-H","article-title":"Effectiveness of Loading Oral Flecainide for Converting Recent-Onset Atrial Fibrillation to Sinus Rhythm in Patients without Organic Heart Disease or with Only Systemic Hypertension","volume":"70","author":"Capucci","year":"1992","journal-title":"Am. J. Cardiol."},{"key":"ref_71","first-page":"41","article-title":"Effectiveness and side effects of the treatment with propafenone and flecainide for recent-onset atrial fibrillation","volume":"2","author":"Romano","year":"2001","journal-title":"Ital. Heart J. Suppl."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0167-5273(02)00467-9","article-title":"Oral Loading Single Dose Flecainide for Pharmacological Cardioversion of Recent-Onset Atrial Fibrillation","volume":"87","author":"Khan","year":"2003","journal-title":"Int. J. Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0735-1097(02)02705-5","article-title":"Amiodarone versus Placebo and Class Ic Drugs for Cardioversion of Recent-Onset Atrial Fibrillation: A Meta-Analysis","volume":"41","author":"Chevalier","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1056\/NEJMoa041233","article-title":"Outpatient Treatment of Recent-Onset Atrial Fibrillation with the \u201cPill-in-the-Pocket\u201d Approach","volume":"351","author":"Alboni","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Valembois, L., Audureau, E., Takeda, A., Jarzebowski, W., Belmin, J., and Lafuente-Lafuente, C. (2019). Antiarrhythmics for Maintaining Sinus Rhythm after Cardioversion of Atrial Fibrillation. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD005049.pub5"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/bph.13807","article-title":"Multiple Targets for Flecainide Action: Implications for Cardiac Arrhythmogenesis","volume":"175","author":"Salvage","year":"2018","journal-title":"Br. J. Pharm."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.hrthm.2017.10.002","article-title":"Clinical Effectiveness of a Systematic \u201cPill-in-the-Pocket\u201d Approach for the Management of Paroxysmal Atrial Fibrillation","volume":"15","author":"Andrade","year":"2018","journal-title":"Heart Rhythm."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/hrt.2009.187963","article-title":"Intravenous Administration of Flecainide or Propafenone in Patients with Recent-Onset Atrial Fibrillation Does Not Predict Adverse Effects during \u201cpill-in-the-Pocket\u201d Treatment","volume":"96","author":"Alboni","year":"2010","journal-title":"Heart"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.amjcard.2019.12.041","article-title":"Use of Flecainide for the Treatment of Atrial Fibrillation","volume":"125","author":"Echt","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1540-8159.2004.00444.x","article-title":"Effects of Pretreatment with Intravenous Flecainide on Efficacy of External Cardioversion of Persistent Atrial Fibrillation","volume":"27","author":"Climent","year":"2004","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0735-1097(98)00577-4","article-title":"Favorable Effects of Flecainide in Transvenous Internal Cardioversion of Atrial Fibrillation","volume":"33","author":"Boriani","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/oxfordjournals.eurheartj.a060852","article-title":"Safety of Flecainide versus Propafenone for the Long-Term Management of Symptomatic Paroxysmal Supraventricular Tachyarrhythmias","volume":"16","author":"Chimienti","year":"1995","journal-title":"Eur. Heart J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"100.e1","DOI":"10.1016\/j.ahj.2007.08.033","article-title":"A Randomized Comparison of Amiodarone and Class IC Antiarrhythmic Drugs to Treat Atrial Fibrillation in Patients Paced for Sinus Node Disease: The Prevention Investigation and Treatment: A Group for Observation and Research on Atrial Arrhythmias (PITAGORA) Trial","volume":"155","author":"Gulizia","year":"2008","journal-title":"Am. Heart J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early Rhythm-Control Therapy in Patients with Atrial Fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"The AFFIRM Investigators (2004). Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation, 109, 1509\u20131513.","DOI":"10.1161\/01.CIR.0000121736.16643.11"},{"key":"ref_86","first-page":"1323","article-title":"A Patient with Asymptomatic Cerebral Lesions During AF Ablation: How Much Should We Worry?","volume":"8","author":"Forleo","year":"2016","journal-title":"J. Atr. Fibrillation"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.hrthm.2020.07.017","article-title":"Is Transesophageal Echocardiography Necessary in Patients Undergoing Ablation of Atrial Fibrillation on an Uninterrupted Direct Oral Anticoagulant Regimen? Results from a Prospective Multicenter Registry","volume":"17","author":"Patel","year":"2020","journal-title":"Heart Rhythm."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1111\/jce.14165","article-title":"Safety of Catheter Ablation for Atrial Fibrillation in the Octogenarian Population","volume":"30","author":"Romero","year":"2019","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/jce.13394","article-title":"Long-term Outcomes of Catheter Ablation in Patients with Longstanding Persistent Atrial Fibrillation Lasting Less than 2 Years","volume":"29","author":"Mohanty","year":"2018","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/jce.13329","article-title":"Procedural Findings and Ablation Outcome in Patients with Atrial Fibrillation Referred after Two or More Failed Catheter Ablations","volume":"28","author":"Mohanty","year":"2017","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/europace\/euq450","article-title":"Mixed Treatment Comparison of Dronedarone, Amiodarone, Sotalol, Flecainide, and Propafenone, for the Management of Atrial Fibrillation","volume":"13","author":"Freemantle","year":"2011","journal-title":"Europace"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(12)60570-4","article-title":"Short-Term versus Long-Term Antiarrhythmic Drug Treatment after Cardioversion of Atrial Fibrillation (Flec-SL): A Prospective, Randomised, Open-Label, Blinded Endpoint Assessment Trial","volume":"380","author":"Kirchhof","year":"2012","journal-title":"Lancet"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1111\/jce.14638","article-title":"Non-pulmonary Vein Triggers in Nonparoxysmal Atrial Fibrillation: Implications of Pathophysiology for Catheter Ablation","volume":"31","author":"Tarantino","year":"2020","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"66A","DOI":"10.1016\/S0002-9149(97)89120-5","article-title":"Comparison of the Safety and Efficacy of Flecamide versus Propafenone in Hospital Out-Patients with Symptomatic Paroxysmal Atrial Fibrillation\/Flutter","volume":"77","author":"Allot","year":"1996","journal-title":"Am. J. Cardiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"53A","DOI":"10.1016\/S0002-9149(97)89118-7","article-title":"Prospective Comparison of Flecainide versus Quinidine for the Treatment of Paroxysmal Atrial Fibrillation\/Flutter","volume":"77","author":"Naccarelli","year":"1996","journal-title":"Am. J. Cardiol."},{"key":"ref_96","first-page":"51","article-title":"A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation","volume":"25","author":"Carunchio","year":"1995","journal-title":"G. Ital. Cardiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00005344-198901000-00005","article-title":"Flecainide Versus Quinidine in the Prevention of Paroxysms of Atrial Fibrillation","volume":"13","author":"Crijns","year":"1989","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/01.CIR.83.1.119","article-title":"Flecainide Acetate Prevents Recurrence of Symptomatic Paroxysmal Supraventricular Tachycardia. The Flecainide Supraventricular Tachycardia Study Group","volume":"83","author":"Henthorn","year":"1991","journal-title":"Circulation"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"539","DOI":"10.7326\/0003-4819-114-7-539","article-title":"Propafenone Treatment of Symptomatic Paroxysmal Supraventricular Arrhythmias: A Randomized, Placebo-Controlled, Crossover Trial in Patients Tolerating Oral Therapy","volume":"114","author":"Pritchett","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"ref_100","first-page":"1493","article-title":"ACC\/AHA\/ESC Guidelines for the Management of Patients with Supraventricular Arrhythmias\u2014Executive Summary","volume":"42","author":"Scheinman","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/0002-8703(88)90032-4","article-title":"Successful Use of Flecainide in Atrial Fibrillation with Rapid Ventricular Rate in the Wolff-Parkinson-White Syndrome","volume":"115","author":"Crijns","year":"1988","journal-title":"Am. Heart J."},{"key":"ref_102","first-page":"556","article-title":"Navx-Guided Cryoablation of Atrial Tachycardia Inside the Left Atrial Appendage","volume":"10","author":"Pandozi","year":"2011","journal-title":"Indian Pacing Electrophysiol. J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0735-1097(10)80090-7","article-title":"Flecainide Acetate Treatment of Paroxysmal Supraventricular Tachycardia and Paroxysmal Atrial Fibrillation: Dose-Response Studies","volume":"17","author":"Pritchett","year":"1991","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_104","first-page":"465","article-title":"European Heart Rhythm Association (EHRA) Consensus Document on the Management of Supraventricular Arrhythmias, Endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci\u00f3n Cardiaca y Electrofisiologia (SOLAECE)","volume":"19","author":"Katritsis","year":"2017","journal-title":"EP Eur."},{"key":"ref_105","first-page":"e124","article-title":"Isolation of the Superior Vena Cava from the Right Atrial Posterior Wall: A Novel Ablation Approach","volume":"20","author":"Gianni","year":"2018","journal-title":"Ep Eur."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0002-9149(91)90527-R","article-title":"Usefulness of Flecainide for Prevention of Paroxysmal Atrial Fibrillation and Flutter","volume":"67","author":"Pietersen","year":"1991","journal-title":"Am. J. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/7\/1456\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:58:08Z","timestamp":1760363888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/7\/1456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":106,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["jcm10071456"],"URL":"https:\/\/doi.org\/10.3390\/jcm10071456","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,2]]}}}